Standard BioTools Affirms FY2024 Sales Guidance to $170.00M-175.00M VS Est. 171.19M
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools has reaffirmed its FY2024 sales guidance, projecting sales between $170 million and $175 million, aligning closely with the estimated $171.19 million.
October 30, 2024 | 8:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Standard BioTools has reaffirmed its FY2024 sales guidance, projecting sales between $170 million and $175 million, which aligns closely with the market estimate of $171.19 million.
The reaffirmation of sales guidance by Standard BioTools suggests stability and predictability in its revenue projections, which aligns with market expectations. This is likely to result in a neutral short-term impact on the stock price as there are no surprises or deviations from what investors anticipated.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100